Oxford University strikes licensing deal with Summit to develop drugs to combat Duchenne Muscular Dystrophy.

Oxford has signed a deal with pharmaceutical firm and spin-out Summit to further develop drugs which tackle Duchenne Muscular Dystrophy. The muscle wasting disease affects one in every 3,500 boys, which leaves patients unable to walk by their teenage years and with a life expectancy of early thirties at the very most. Currently, there is…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.